|
Synonyms: CNTO 136 | CNTO-136 | Plivensia (proposed trade name)
Compound class:
Antibody
Comment: Sirukumab is a monoclonal antibody directed against interleukin 6 (IL-6), in development as an immunomodulator for the treatment of rheumatoid arthritis (RA). It is also being tested as an immunopsychiatry therapy to treat depression.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence BLAST search using the heavy chain variable region of sirukumab provides100% match to a sequence claimed in patent US7560112 [1], and to the antibody with designation AME-19a. |
| Immunopharmacology Comments |
| Sirukumab is an investigational immunomodulator, with the most advanced trials being in patients with rheumatoid arthritis. Evidence supporting the potential anti-depressive action of IL-6 neutralising antibody therapy is reported in [7]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Polymyalgia rheumatica |
Disease Ontology:
DOID:853 |
Phase 3 clinical candidate for PMR (see NCT02899026). | |
| Temporal arteritis |
Disease Ontology:
DOID:13375 OMIM: 187360 Orphanet: ORPHA397 |
Phase 3 clinical candidate for temporal arteritis (giant cell arteritis)- see NCT02531633 | |
| Major depressive disorder; MDD |
Disease Ontology:
DOID:1470 OMIM: 608516 |
Phase 2 clinical candidate for MDD (see NCT02473289). | |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Phase 3 clinical candidate for RA (see NCT01856309). | |
